The European Commission has signed today an agreement worth €20 million with the French biopharmaceutical company Fabentech.
The investment will be routed through the EU’s Health Emergency Preparedness and Response Authority (HERA) and the European Investment Bank, and will help Fabentech develop and deploy its broad-spectrum therapeutics to combat biological threats to public health.
The agreement is the first in its kind under HERA Invest. More investments are in the pipeline with other European companies, with the goal to stimulate innovation to respond to priority health threats, such as pathogens with high pandemic potential, chemical, biological, radiological and nuclear (CBRN) threats, and resistance to antibiotics.
https://ec.europa.eu/commission/presscorner/detail/en/ip_24_5023